Using alone: what is actually known

Most of what is known about psychedelics from controlled research comes from a specific kind of setting: participants who were medically and psychologically screened beforehand, prepared by trained staff, and supervised throughout the experience by at least one, often two, present clinicians. Guidelines for this kind of research spell out screening criteria, staff training, and monitoring precisely because the setting is understood to be part of what keeps risk manageable.

That is worth being honest about. When a study reports a rate of difficult or adverse experiences, that rate describes people who had a screened history, a prepared setting, and trained supervision — not the general population of anyone who takes something on a given night. A systematic review of adverse events in clinical treatment settings found real but generally manageable risks under those conditions; the same review does not, and cannot, tell you what those risks look like without supervision.

None of this means solo or unsupervised use is unsafe by definition, or that everyone doing it is taking on outsized risk. It means the research most often cited to reassure people was not conducted on people using alone, and treating those numbers as if they transfer directly is not supported by what the studies actually measured. A more honest framing: supervision is one of several risk-reducing factors researchers have consistently built into their protocols, and its absence is something worth planning around rather than dismissing.

If you are using alone, the specific things a present person would otherwise catch — noticing a physical problem, calling for help if you cannot, telling you afterward what actually happened — become yours to plan around instead. Telling one person when to expect to hear from you, keeping a phone charged and reachable, and choosing a space you will not need to leave are the plainest versions of that.